Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
Open-label Study to Assess the Effectiveness of Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis (IPF).
- First Posted Date
- 2017-07-06
- Last Posted Date
- 2020-11-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 60
- Registration Number
- NCT03208933
- Locations
- 🇷🇺
Regional State Budgetary Institution of Healthcare "Regional Cinilcal Hospital"; Pulmonology, Barnaul, Altaj, Russian Federation
🇷🇺Pulmonologii NII FMBA of Russia, Moscow, Moskovskaja Oblast, Russian Federation
🇷🇺Budget Institution of Healthcare of Voronezh Region "Voronezh Regional Clinical Hospital #1", Voronezh, Russian Federation
An Extension Study to Evaluate Long-Term Safety of Subcutaneous (SC) Tocilizumab in Participants With Giant Cell Arteritis (GCA)
- First Posted Date
- 2017-06-28
- Last Posted Date
- 2020-09-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 3
- Registration Number
- NCT03202368
- Locations
- 🇫🇷
Hopital Claude Huriez; Internal Medicine, Lille, France
🇫🇷Hopital Emile Muller; Medecine Interne, Mulhouse, France
🇫🇷Hopital La Cavale Blanche; Rhumatologie, Brest, France
A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer
- Conditions
- Triple-negative Breast Cancer
- Interventions
- First Posted Date
- 2017-06-23
- Last Posted Date
- 2023-10-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 333
- Registration Number
- NCT03197935
- Locations
- 🇩🇪
Ambulantes Tumorzentrum Spandau; Dres. Benno Mohr und Uwe Peters, Berlin, Germany
🇬🇧Leicester Royal Infirmary, Leicester, United Kingdom
🇦🇺Fiona Stanley Hospital; FSH Cancer Centre Clinical Trials Unit, Bull Creek, Western Australia, Australia
A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer
- First Posted Date
- 2017-06-21
- Last Posted Date
- 2024-12-30
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 200
- Registration Number
- NCT03194893
- Locations
- 🇫🇷
Centre Georges François Leclerc, Dijon, France
🇫🇷CHU de Toulouse - Hôpital Larrey, Toulouse Cedex 9, France
🇫🇷Hopital Robert Schuman, Vantoux, France
A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
- Conditions
- Pancreatic Adenocarcinoma
- Interventions
- First Posted Date
- 2017-06-20
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 340
- Registration Number
- NCT03193190
- Locations
- 🇺🇸
Uni of Chicago Medical Center; Room M454, Chicago, Illinois, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2017-06-19
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 453
- Registration Number
- NCT03191786
- Locations
- 🇩🇪
LungenClinic Großhansdorf GmbH; Klinische Forschung, Großhansdorf, Germany
🇦🇷Fundación CENIT para la Investigación en Neurociencias, Buenos Aires, Argentina
🇦🇷Hospital Privado de Comunidad, Mar del Plata, Argentina
A Study to Evaluate the Safety and Tolerability of Prophylactic Emicizumab in Hemophilia A Patients With Inhibitors
- First Posted Date
- 2017-06-19
- Last Posted Date
- 2021-06-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 195
- Registration Number
- NCT03191799
- Locations
- 🇨🇦
Kaye Edmonton Clinic, Edmonton, Alberta, Canada
🇩🇪Universitätsklinikum Bonn; Institut für Experimentelle Hämatologie und Transfusionsmedizin, Bonn, Germany
🇩🇪Vivantes Klinikum im Friedrichshain - Landsberger Allee, Angiologie und Hämostaseologie, Berlin, Germany
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GDC-0853 in Healthy Japanese and Caucasian Participants
- Conditions
- Healthy Volunteer
- Interventions
- Drug: GDC-0853Drug: Placebo
- First Posted Date
- 2017-06-15
- Last Posted Date
- 2019-08-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 32
- Registration Number
- NCT03188783
- Locations
- 🇺🇸
West Coast Clinical Trials, Cypress, California, United States
A Study to Investigate the Intrapulmonary Lung Penetration of Nacubactam in Healthy Participants
- Conditions
- Gram-negative Bacterial Infections
- Interventions
- First Posted Date
- 2017-06-09
- Last Posted Date
- 2018-04-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 21
- Registration Number
- NCT03182504
- Locations
- 🇺🇸
Pulmonary Associates Clinical Trials (PACT), Phoenix, Arizona, United States
A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2017-06-07
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1000
- Registration Number
- NCT03178552
- Locations
- 🇺🇸
UC Davis; Comprehensive Cancer Center, Sacramento, California, United States
🇺🇸Rocky Mountain Cancer Center, Denver, Colorado, United States
🇺🇸SCRI Florida Cancer Specialists South, Fort Myers, Florida, United States